Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Hikal Ltd

Hikal Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)383.40
  • Today's Change2.75 / 0.72%
  • Shares traded96.70k
  • 1 Year change+37.37%
  • Beta1.6615
Data delayed at least 15 minutes, as of Nov 01 2024 13:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Hikal Limited is an India-based company, which is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Pharmaceuticals segment produces active pharmaceutical ingredients. Its facilities are in Jigani, Bangalore and Panoli, Gujrat. The Crop protection segment produces pesticides and herbicides. Its facilities are in Taloja, Mahad, Maharashtra and Panoli, Gujarat. Its human health product categories include anti-convulsant, anti-emetic, anti-histaminic, anti-depressant, anti-psychotic, anti-lipemic, hemorheologic, anti-diabetic, anti-thrombotic, anti-viral, anti-inflammatory, analgesic and anti-parasitic. Its animal health product categories include anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone and NSAID. Its crop protection product categories include algaecide, biocide, fungicide, herbicide, insecticide and intermediate.

  • Revenue in INR (TTM)18.03bn
  • Net income in INR677.82m
  • Incorporated1988
  • Employees2.06k
  • Location
    Hikal LtdGreat Eastern ChambersSector 11, CBD-BelapurNAVI MUMBAI 400614IndiaIND
  • Phone+91 2 230973100
  • Fax+91 2 227574277
  • Websitehttps://www.hikal.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Indoco Remedies Ltd17.73bn320.40m28.60bn5.93k93.032.6320.981.613.343.34175.26118.230.81941.524.512,989,727.001.366.881.999.8568.3465.591.666.930.81421.710.433914.028.9113.41-30.78--34.5437.97
Dishman Carbogen Amcis Ltd24.16bn-2.48bn30.54bn1.13k----176.821.26-15.81-15.81154.06--------21,344,260.00---0.3986---0.488879.3073.83-10.27-1.54---0.7216----8.414.91-414.93---0.3175--
RPG Life Sciences Limited6.00bn923.20m41.48bn1.27k44.93--37.556.9255.8255.82362.60--------4,721,969.00--16.07--21.7768.4262.9915.3911.99--220.43--29.2713.5012.0129.6051.9828.6046.14
Solara Active Pharma Sciences Ltd12.22bn-5.36bn42.96bn2.16k--2.57--3.52-137.13-137.13320.29301.630.47311.772.695,667,023.00-20.76-2.44-36.40-3.8438.7041.16-43.89-4.490.448-1.300.4355---10.73-1.45-2,458.12---4.81--
Jeena Sikho Lifecare Ltd-100.00bn-100.00bn43.37bn1.23k--137.18----------12.72------------------------0.8228--0.2681--43.84--77.37------
Morepen Laboratories Ltd17.45bn1.18bn43.77bn1.62k34.57--29.252.512.312.3134.26--------10,749,300.00--7.90--13.3437.8633.346.775.49--33.34--0.0019.2517.08148.6327.2247.03--
Gufic BioSciences Ltd8.14bn863.69m43.97bn1.45k50.41--42.505.408.708.7081.95--------5,624,707.00--11.46--19.2152.3945.7910.6010.46--8.09--1.3116.8018.128.0731.4653.8314.87
Aarti Drugs Ltd23.80bn1.52bn44.19bn1.06k29.133.4621.491.8616.6216.62259.74139.960.99543.163.4322,364,630.006.379.739.6215.7834.6022.236.408.251.016.830.3159---6.9010.133.0713.8224.96--
Innova Captab Ltd11.42bn1.06bn44.50bn--32.82--35.813.9023.6923.69236.62------------10.82--18.3833.3825.189.308.04--8.89----16.7224.9038.8436.55104.14--
SeQuent Scientific Ltd14.27bn54.87m45.44bn1.20k853.41--58.503.190.21370.213757.18--------11,939,190.00--1.09--1.7645.3841.970.99021.18--0.9009--35.06-3.605.6870.40--6.96--
Hikal Ltd18.03bn677.82m46.93bn2.06k69.28--24.772.605.495.49145.97--------8,749,879.00--5.07--7.5153.0646.783.765.86--2.45--12.19-11.792.34-11.20-7.559.720.00
Supriya Lifescience Ltd6.25bn1.58bn50.18bn448.0031.915.5428.718.0319.5419.5477.55112.560.67372.016.5613,950,510.0016.9819.0818.3824.0466.8157.1225.2024.714.05111.460.0062.8823.7415.4732.5624.7583.79--
Aarti Pharmalabs Ltd19.68bn2.28bn57.96bn1.63k25.413.1218.882.9525.1625.16217.12204.880.77331.624.5912,095,750.008.96--11.86--45.56--11.59--0.961117.120.1723---4.76--12.10------
Unichem Laboratories Ltd17.28bn-605.50m58.55bn3.19k----112.073.39-8.59-8.59245.15--------5,410,587.00---1.67---2.0362.0056.18-3.50-3.99--0.1401----26.947.6465.15---35.00--
Data as of Nov 01 2024. Currency figures normalised to Hikal Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

7.56%Per cent of shares held by top holders
HolderShares% Held
Tata Asset Management Pvt Ltd.as of 30 Sep 20243.30m2.68%
Norges Bank Investment Managementas of 30 Sep 20232.54m2.06%
Th�l�me Partners LLPas of 30 Sep 20231.29m1.05%
Dimensional Fund Advisors LPas of 03 Oct 20241.03m0.83%
ICICI Prudential Asset Management Co. Ltd.as of 30 Sep 2024375.52k0.31%
Fiduciary Management, Inc.as of 31 Aug 2024216.19k0.18%
Kotak Mahindra Asset Management Co. Ltd.as of 30 Sep 2024210.00k0.17%
BlackRock Advisors (UK) Ltd.as of 03 Oct 2024172.84k0.14%
BlackRock Fund Advisorsas of 03 Oct 2024101.32k0.08%
Mellon Investments Corp.as of 03 Oct 202487.90k0.07%
More ▼
Data from 30 Jun 2024 - 15 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.